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Introduction
In type 1 diabetes, autoimmune destruction 
of the beta cells of the pancreas results in 
insulin deficiency and insulin dependence. 
The ultimate aim of treatment is to provide 
type 1 diabetes patients with an insulin 
therapy which mimics the physiological 
basal and meal-related insulin secretion from 
the pancreas and maintain normoglycaemia 
thus preventing the development of 
complications. The latest clinical guidance 
on the diagnosis and management of type 
1 diabetes in adults issued by the National 
Institute for Health and Care Excellence 
(NICE) in August 20151 and the Standards 
of Medical Care in Diabetes 2016 issued by 
the American Diabetes Association2 both 
recommend insulin therapy in the form 
of multiple dose insulin (MDI) injection 
of a basal-bolus regimen or continuous 
subcutaneous insulin infusion (CSII) for 
adult type 1 diabetes patients. 
Multiple Dose Insulin (MDI) Injection  
MDI regime includes a long acting insulin 
injected once or twice daily (the basal 
insulin), together with a rapid acting 
insulin injected at meal times (the bolus 
insulin) translating to at least 3 to 4 insulin 
injections per day. To achieve optimal 
glycaemic control with this regimen, 
the rapid acting insulin dose should be 
calculated according to the carbohydrate 
content of meals, the glucose level before 
the meal and the expected level of physical 
activity.2 This highlights the importance 
of educating the patient who is being 
considered for MDI on the various aspects 
of diabetes self-management including 
carbohydrate counting, frequent blood 
glucose monitoring, pre-meal and post-
meal glucose targets, and insulin dose 
adjustments in relation to exercise and 
general health status. Education minimises 
the episodes of hypoglycaemia that are 
more likely to occur with intensive insulin 
regimes.3 Use of insulin analogues, rather 
than human sequence insulin, for the MDI 
regimen has been associated with decreased 
rates of hypoglycaemia. Type 1 diabetes 
patients, who reported at least 2 episodes 
of severe hypoglycaemia in the previous 
12 months, had a reduced rate of severe 
hypoglycaemic episodes by 0.51 episodes 
(95% CI 0.19-0.84) per patient-year or 29% 
(95% CI 11-48; p=0.010) when treated with 
insulin analogues for one year as compared 
to treatment with human sequence insulin 
for one year.4
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Abstract
Insulin therapy in type 1 diabetes is recommended as multiple dose 
injections (MDI) or continuous subcutaneous insulin infusion (CSII) to 
deliver a basal background insulin dose together with bolus insulin doses 
prior to meals. Use of automated bolus calculators and / or continuous 
glucose monitors with MDI have been shown to improve glycaemic control 
in type 1 diabetes patients. Several models of insulin pumps with various 
features are available. CSII offers greater flexibility with a reduced 
number of injections but in view of its complexity, patients who will 
benefit from this therapy need to be carefully selected. 
Insulin therapy in adult 
type 1 diabetes patients: 
Multiple Dose Insulin Injection (MDI) 
or Continuous Subcutaneous Insulin 
Infusion (CSII)
Educational aims
•	 To give an overview of MDI therapy and introduce associated technologies
•	 To highlight the various types of insulin pumps available
•	 To summarise clinical evidence regarding treatment with MDI and CSII in 
type 1 diabetes patients
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With the availability of automated 
bolus calculators, the dose of insulin that 
is required prior to meals is recommended 
to the patient and generated using patient-
specific data combined with meal-specific 
data. The patient specific data is pre-set 
and includes carbohydrate to insulin ratios, 
insulin sensitivity factors and blood glucose 
targets. On the other hand, meal-specific 
data includes carbohydrate intake and 
pre-meal glucose levels. Automated bolus 
calculators facilitate the complex and 
laborious task of calculating bolus insulin 
doses prior to each meal.5 In the multicentre 
randomised controlled trial ABACUS, the 
use of a bolus advisor in patients with 
diabetes on MDI therapy was associated 
with a significantly greater percentage of 
patients who achieved >0.5% reduction in 
HbA1c (56.0 vs 34.4%; P<0.01) without 
an increase in severe hypoglycaemia and 
significantly greater treatment satisfaction 
when compared to patients with diabetes 
on MDI therapy who manually calculated the 
bolus insulin dose.6 Type 1 diabetes patients 
on MDI therapy who used an automated 
bolus calculator had decreased fear of 
hypoglycaemia and increased confidence in 
bolus dose accuracy in a separate study.7
Another tool that has been shown to 
be beneficial in self-management of type 
1 diabetes is real time continuous glucose 
monitors (CGM). These display the current 
interstitial glucose level from a subcutaneous 
glucose sensor, provide glucose trends based 
on changes in previous glucose readings and 
alarm at pre-set glucose values and following 
rapid changes in glucose readings. These 
devices still require sensor calibration with 
self-monitoring of blood glucose (SMBG) at 
least 12 hourly. In a randomised controlled 
trial comparing CGM to SMBG in patients 
with type 1 diabetes with poor metabolic 
control treated with MDI or CSII, the CGM 
group showed improved glycaemic control 
with 50% of patients achieving a 1% 
minimum reduction in HbA1c and 25% of 
patients achieving a 2% minimum reduction 
in HbA1c.8 The Juvenile Diabetes Research 
Foundation (JDRF) CGM randomised trial, 
also registered improvement in glycaemic 
control with CGM use, without an increase 
in severe hypoglycaemia, when compared to 
SBGM (mean difference in change in HbA1c 
−0.53 %; 95 % CI, −0.71 to −0.35, P<0.001) 
in type 1 diabetes patients >25 years of age 
on MDI or CSII with a baseline HbA1c of 
7-10%.9 The greatest reductions in HbA1c 
associated with CGM use were documented in 
patients who had the highest HbA1c and in 
frequent users of CGM.10 
Continuous subcutaneous insulin infusion 
(CSII)
Delivery of CSII requires an external pump 
device which includes an insulin pump, 
an insulin storage reservoir and an insulin 
infusion set consisting of a tubing set 
and a cannula for subcutaneous insertion. 
The pump delivers a basal rate of insulin, 
which can be programmed to vary according 
to different basal insulin requirement 
throughout the day and night, with bolus 
doses at meal times triggered manually by 
the patient. The delivery of the bolus can 
be of various types and duration including 
normal (standard), extended (square 
wave) and dual wave, depending on the 
macronutrient composition of the meal. 
There are several models of insulin pumps 
available with various features, alerts and 
alarms. Bolus calculators can be integrated 
in insulin pumps with the insulin on board 
(IOB) calculation available in most insulin 
pump models. The IOB is the calculation of 
how much insulin is still active from previous 
bolus doses. 
Sensor-augmented insulin pumps (SAP), 
which incorporate continuous subcutaneous 
glucose monitors, have been shown to 
improve glycaemic control with frequent 
CGM use, but whether the associated risk 
of hypoglycaemia is increased or not is 
unclear. In a randomised treat-to-target 
study of patients with type 1 diabetes, use 
of a SAP for 6 months was associated with a 
significant reduction in HbA1c (P = 0.0456) 
in patients who utilised the CGM sensors for 
>60% of the time, and an increased number 
of severe hypoglycaemic events (11 events 
in the SAP group vs 4 events in the CSII and 
SMBG group) (P = 0.04), when compared 
to insulin pump therapy with SMBG. The 
probability of a 0.5% reduction in HbA1c 
was increased by 41% for each 10% increase 
in CGM sensor compliance.11 Significant 
improvement in HbA1c in patients using 
SAP who utilised CGM for ≥70% of the time 
(P = 0.004) (SAP group -0.96 ±0.93%, P < 
0.001; CSII and SBGM group -0.55 ±0.93%, 
P < 0.001) was confirmed in the RealTrend 
Study which studied patients during their 
initial 6 months of insulin pump therapy 
with SAP compared to CSII and SBGM. No 
associated increase in hypoglycaemic events 
was reported in this study.12 
SAPs with the added function of low-
glucose suspension have been associated 
with improved rates of hypoglycaemia. These 
devices stop insulin delivery automatically, 
for up to 2 hours, once the glucose level 
falls below a certain threshold. The rate of 
moderate and severe hypoglycaemia was 
found to be reduced in type 1 diabetes 
patients on SAP with low glucose suspension 
compared to SAP only, with an adjusted 
incidence rate per 100 patient-month of 34.2 
(95% CI, 22.0-53.3) for patients using SAP 
only and 9.5 (95% CI, 5.2-17.4) for patients 
using SAP with low-glucose suspension.13 
In the ASPIRE In-Home study, the rate and 
severity of nocturnal hypoglycaemia was 
also documented to be decreased in type 1 
diabetes patients using SAP with low-glucose 
suspension who had improving or low HbA1c 
at baseline, compared with SAP alone.14 
Closed Loop (CL) insulin delivery systems 
or ‘Artificial Pancreas’ comprise a CSII, a 
CGM and complex algorithms to control 
glucose and ensure safety, incorporated in 
one device or separately, fully automated or 
combining user input with automated periods 
of insulin administration.15 During periods of 
automated insulin administration, the rate 
of insulin delivery is determined by real-
time interstitial glucose levels which feed 
into a control algorithm.16  Use of CL insulin 
delivery system day-and-night for 12 weeks, 
in 33 adult type 1 diabetes patients resulted 
in a lower mean glucose level (difference, 
-0.6mmol/L; 95% CI, -17 to -6; P<0.001), 
lower mean HbA1c (difference, -0.3%; 95% 
CI, -0.5 to -0.1; P=0.002), less time spent 
with glucose <3.5mmol/L (39% lower; 95% 
CI, 24 to 51; P<0.001) and more time spent 
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in target glucose range (95% confidence 
interval [CI], 8.1 to 13.8) (P<0.001) when 
compared to SAP therapy.17 
While CSII offers the advantages of 
greater flexibility with variable rates of 
basal insulin delivery and frequent boluses 
of various type and duration with fewer 
injections, it is also associated with a 
number of possible complications including 
cannula site reactions and infections, insulin 
infusion blockage and pump malfunction. 
With the complexity of intensive insulin 
therapy by CSII and with the possibility 
of associated complications which might 
result in severe adverse events like diabetes 
ketoacidosis, CSII therapy requires the 
selection of highly motivated patients 
who will benefit from this mode of insulin 
delivery safely and effectively. CSII therapy 
should be initiated in the setting of a 
highly specialised multidisciplinary diabetes 
management team whose members are 
specifically trained in insulin pump therapy 
to provide selected patients with the 
required support, education and training on 
the safe use of insulin pumps.
Multiple Dose Injection (MDI) vs 
Continuous subcutaneous insulin infusion 
(CSII)
Several systematic reviews and meta-analyses 
have been carried out to compare insulin 
treatment with MDI or CSII in patients with 
type 1 diabetes. A Cochrane systematic 
review which included 23 studies found a 
significant difference in HbA1c (weighted 
mean difference -0.3% (95% confidence 
interval -0.1 to -0.4), reduced severe 
hypoglycaemia and better quality of life in 
patients using CSII compared to MDI.18 In 
a previous systematic review and meta-
analysis, Fatourechi showed that adult 
patients with type 1 diabetes on CSII had 
slightly reduced HbA1c (random-effects 
weighted mean difference, -0.2%; 95% 
confidence interval (CI), -0.3, -0.1) with 
no difference in the risk of hypoglycaemia 
when compared to patients on MDI.19 In a 
meta-analysis by Pickup et al, the rate of 
severe hypoglycaemia was less in patients 
on CSII with the greatest reduction noted 
in patients with the highest initial rates of 
severe hypoglycaemia on MDI and in patients 
with long diabetes duration. The greatest 
reduction in HbA1c was observed in patients 
who had highest HbA1c levels on MDI.20 
Adult type 1 diabetes patients on CSII were 
found to have a greater reduction in HbA1c 
without increased hypoglycaemia rates and 
with a reduced total daily insulin dose when 
compared to patients on MDI, in a systematic 
review and meta-analysis by Jeitler et al.21 
These meta-analyses are limited since older 
studies using old insulin pump technology, 
studies of short duration, small studies and 
studies comparing MDI therapy with human 
sequence insulin to insulin analogues in CSII 
were often included in the analysis. 
Evidence from observational studies 
points towards reduced HbA1c levels and 
statistically significant reduced rates of 
severe hypoglycaemia with CSII when 
compared to MDI.22 
The ongoing Relative Effectiveness of 
Pumps Over MDI and Structured Education 
(REPOSE) trial, a randomised controlled 
trial of 280 adult type 1 diabetes patients, 
recruited from 7 UK centres, assigned to 
either analogue MDI or analogue CSII 
following standard structured training in 
insulin adjustment and followed up for 
2 years,23 is expected to address several 
limitations of previous randomised controlled 
trials of MDI vs CSII, highlighting risks and 
benefits of both therapies.  
Current guidelines for CSII therapy in 
adult type 1 diabetes patients recommend 
treatment with CSII in patients who have 
persistently high HbA1c despite intensive 
therapy with MDI and in patients with 
disabling hypoglycaemia.24,25 The American 
AACE/ACE recommendations for CSII therapy 
are broader but also specify characteristics 
of patients who would not benefit from pump 
therapy.25 
Conclusion
Type 1 diabetes is a chronic disease that 
requires a lot of input from the patient 
Key points
•	 Insulin therapy in type 1 diabetes is recommended as multiple dose insulin (MDI) 
injections or as continuous subcutaneous insulin infusion (CSII) 
•	 MDI consists of a once or twice daily basal long acting insulin dose and a bolus rapid 
acting insulin dose prior to meals, calculated according to the carbohydrate content 
of meals, the glucose level before the meal and the expected level of physical activity
•	 Automated bolus calculators and / or continuous glucose monitors have been shown 
to improve glycaemic control in type 1 diabetes patients on MDI
•	 Treatment with CSII has been associated with improved glycaemic control and reduced 
rates of severe hypoglycaemia when compared to MDI in observational studies
•	 CSII should only be initiated in the setting of a highly specialised multidisciplinary 
diabetes management team whose members are specifically trained in insulin pump 
therapy 
•	 CSII therapy requires the selection of highly motivated patients who will benefit from 
this mode of insulin delivery safely and effectively
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together with regular review and support 
by the specialised diabetes teams who 
provide intensive education and training 
and recommend the most suitable insulin 
type, insulin delivery and accurate, reliable 
and safe technologies that best serve 
each individual patient based on clinical 
evidence and tailored to the patient’s 
lifestyle, commitment, motivation, skills and 
expectations while striving to reduce disease 
burden and preserve quality of life.
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